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Four  studies  were  conducted  to determine  the  pharmacokinetic  characteristics  and  in  vitro
metabolism  of  eprinomectin,  a semi-synthetic  avermectin,  in  cats.  Pharmacokinetic  param-
eters including  bioavailability  of  eprinomectin  were  determined  in a parallel  study  design
comprised  of  one  group  of eight  cats  which  were  treated  once  topically  at 0.12  mL/kg
bodyweight  with  BROADLINE®, a novel  combination  product  (ﬁpronil  8.3%  (w/v),  (S)-
methoprene  10%  (w/v),  eprinomectin  0.4% (w/v)  and  praziquantel  8.3%  (w/v)),  delivering  a
dose  of  0.5  mg  eprinomectin  per  kg body  weight,  and a group  of  six  cats  which  received  0.4%
(w/v) eprinomectin  at 0.4  mg/kg  bodyweight  once  by intravenous  injection.  For  cats  treated
by  topical  application,  the  average  eprinomectin  (B1a component)  maximum  plasma  con-
centration  (Cmax)  was  20 ng/mL.  The  maximum  concentrations  were  reached  24 h  after
dosing  in the  majority  of the animals  (six  of  eight  cats). The  average  terminal  half-life  was
114 h  due  to  slow  absorption  (‘ﬂip-ﬂop’  kinetics).  Following  intravenous  administration  the
average  Cmax was  503  ng/mL  at  5 min  post-dose,  and  the mean  elimination  half-life  was 23  h.
Eprinomectin  was widely  distributed  with  a  mean  volume  of distribution  of  2390  mL/kg,
and  the clearance  rate  was  81  mL/h/kg.  Mean  areas  under  the plasma  concentration  versus
time curves  extrapolated  to inﬁnity  were  2100  ng h/mL  and  5160  ng h/mL  for  the  topical
and  intravenous  doses,  respectively.  Topical  eprinomectin  was  absorbed  with  an  average
absolute  bioavailability  of  31%.  In a second  parallel  design  study,  the  dose  proportional-
ity  of  eprinomectin  after  single  topical  administration  of BROADLINE® was  studied.  Four
groups of eight  cats  each  were  treated  once  topically  with  0.5, 1, 2  or 5  times  the  minimum
recommended  dose of  the combination,  0.12  mL/kg  bodyweight.  Based  on  comparison  of
areas under  the  plasma  concentration  versus  time  curves  from  the  time  of dosing  to  the  last
time  point  at  which  eprinomectin  B1a was  quantiﬁed,  and  Cmax, dose  proportionality  was
established.  In addition,  the metabolic  pathway  of  eprinomectin  using  cat liver  microsomes,
and plasma  protein  binding  using  cat, rat, and  dog  plasma  were  studied  in  vitro.  Results  of
the  analyses  of  eprinomectin  B1a described  here showed  that  it is metabolically  stable  and
highly protein  bound  (>99%),  and thus  likely  to be, as with  other  species,  excreted  mainly
as unchanged  parent  drug
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. Introduction
Cats are susceptible to a number of internal parasites,
uch as intestinal worms and heartworms, and external
arasites, such as ﬂeas and ticks, which may  pose a health
isk to the animal and in some cases humans. While clini-
al signs vary or may  be negligible, it is important to treat
arasitic infections to reduce any serious and/or long term
ealth effects the cat may  experience. There are a number
f veterinary products available that target only internal
elminth parasites or prevent heartworm infections, and
roducts that target external parasites only. Only a few
roducts concomitantly target both, endo- and ectopar-
sites, and meet customer expectations with regards to
hat can be achieved in terms of treatment and preven-
ion of disease (Meinke, 2001; Pipano, 2003). Merial has
eveloped Broadline®, a novel topical combination formu-
ation of ﬁpronil 8.3% (w/v), (S)-methoprene 10% (w/v),
prinomectin 0.4% (w/v), praziquantel 8.3% (w/v) for cats
uffering from, or at risk of, mixed parasitic infections.
n this formulation eprinomectin provides activity for the
reatment and control of intestinal and urinary bladder
orms, and the prevention of heartworm disease in cats
nd kittens.
Eprinomectin, developed exclusively for veterinary
edicine use, is a potent parasiticide and was developed
s the ﬁrst endectocide for cattle including lactating dairy
ows. Eprinomectin was registered as the topical solution
PRINEX® Pour-On (Merial) for the treatment and control
f certain gastrointestinal roundworms, lungworms, eye-
orms, cattle grubs, lice, mange mites and ﬂies in and
n cattle (Shoop et al., 1996a; Shoop and Soll, 2002), and
ore recently as an injectable formulation, LONGRANGETM
Merial), providing efﬁcacy against cattle parasites for
p to 150 days (Soll et al., 2013). Eprinomectin (epri-
omectin B1), 4′′-epiacetylamino-4′′-deoxyavermectin B1,
elongs to the macrolide class of parasiticides and the
vermectin family. It is a semi-synthetic derivative of aver-
ectin B1 or abamectin. It consists of two homologs, B1a
nd B1b, which differ by a methylene group, and it is
eﬁned as no less than 90% B1a and no more than 10%
1b (EMEA, 1996). Eprinomectin B1a, the major compo-
ent was used for quantitative analysis for this study.
lthough the exact mechanism of action of eprinomectin is
ot known, this class of macrocyclic lactone drugs mediates
ts nematocidal effect via interaction with a common recep-
or molecule; macrocyclic lactones essentially irreversibly
pen glutamate-gated chloride ion channels resulting in
yperpolarization. Recently, the binding site of a macro-
yclic lactone (ivermectin) and the structure of a glutamate
ated ion channel were determined (Wolstenholme, 2012).
his research contributes to our understanding of these
on channels and their modulation by macrocyclic lactones
uch as eprinomectin.
While the use of eprinomectin has been characterized
n several species other than cattle, it is a new anthelmintic
ompound for cats. In both laboratory and ﬁeld studies,
t has been shown to be well tolerated in adult cats and
ittens. To further characterize the use of eprinomectin
n cats, two in vivo studies were conducted to evalu-
te the pharmacokinetic proﬁle, and two in vitro studiesasitology 202 (2014) 2–9 3
were conducted to evaluate biotransformation and protein
binding.
2. Materials and methods
2.1. Evaluation of pharmacokinetics including dose
proportionality
2.1.1. Experimental animals
In total, 56 purpose-bred European Short Hair cats were
selected for use in the two  studies. Animals were randomly
allocated to treatment groups following blocking based on
pre-treatment body weight within sex category (male and
male castrated; female and female spayed). Details of the
animals as grouped following allocation in both studies are
given in Table 1. None of the animals had been treated with
parasiticides in the three months prior to treatment. Cats
were acclimated to the study facilities for seven days and
were housed individually in cages. Food was  provided once
daily as per the manufacturer’s recommendation; drink-
ing water was  available at all times. All cats were observed
hourly for 4 h after treatment application and once daily
throughout study for health problems or adverse events.
All animals were managed similarly and with due regard
for their welfare. Animals were handled in compliance with
local Ethics Committee approvals and other applicable local
regulations and requirements.
2.1.2. Dosing and sample collection
In a parallel design study, one group of eight cats was
treated with the combination product, ﬁpronil 8.3% (w/v),
(S)-methoprene 10% (w/v), eprinomectin 0.4% (w/v) and
praziquantel 8.3% (w/v) (Broadline®, Merial), once topically
at 0.12 mL/kg bodyweight delivering a dose of 0.5 mg epri-
nomectin per kg bodyweight, and one group of six cats
was treated with 0.4% (w/v) eprinomectin at 0.10 mL/kg
bodyweight (equivalent to 0.4 mg  eprinomectin per kg
bodyweight) once by intravenous (IV) injection. The topi-
cal dose corresponded to the intended minimum label dose
(0.5 mg/kg) of the novel combination formulation and was
applied directly onto the skin in the midline of the neck,
between the base of the skull and the shoulder blades in a
single spot. The IV injection (0.4 mg/kg eprinomectin) was
given in the cephalic vein. Blood samples were collected
prior to treatment and at 5 and 30 min  (IV-treated cats
only), 1, 2, 4, 8 (topical-treated cats only), 10, and 24 h, and
2, 3, 5, 7, 10, 12, 14, 16 and 18 days following treatment
administration.
Dose proportionality of eprinomectin after single topi-
cal administration of the combination product was  studied
in a parallel design study. Four groups of eight cats
each were treated once topically with the topical com-
bination product at 0.06 mL/kg, 0.12 mL/kg, 0.24 mL/kg or
0.60 mL/kg bodyweight), respectively (equivalent to 0.25,
0.5, 1.0 or 2.5 mg  eprinomectin per kg bodyweight), repre-
senting 0.5, 1, 2 and 5 times the intended minimum label
dose. Treatments were applied as described before. Blood
samples were collected prior to treatment and at 1, 2, 4, 8,
10, and 24 h, and 2, 3, 5, 7, 10, 12, 14, 16 and 18 days follow-
ing treatment application. In both studies, blood samples
were drawn from the jugular veins and collected in lithium
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Table 1
Summary characteristics of experimental cats: treatment and treatment dosage, sex, age and pre-treatment bodyweight.
Study/group/dosage Sexc ∼Age (months) Pre-treatment bodyweight (kg)
Study 1 – Pharmacokinetics and bioavailability
Topical FMEPa at 0.12 mL/kg 4MC, 4FS 7–36 3.18–5.25
Intravenous Eb at 0.10 mL/kg 3MC, 3FS 18–29 3.44–4.91
Study 2 – Dose proportionality
Topical FMEPa at 0.06 mL/kg 2M, 2MC, 2F, 2FS 9–27 2.74–5.77
Topical FMEPa at 0.12 mL/kg 1M,  3MC, 3F, 1FS 12–34 2.94–5.06
Topical FMEPa at 0.24 mL/kg 1M,  3MC, 3F, 1FS 8–31 2.62–5.07
Topical FMEPa at 0.60 mL/kg 1M,  3MC, 2F, 2FS 11–27 2.79–5.50
/v) and a Fipronil 8.3% (w/v), (S)-methoprene 10% (w/v), eprinomectin 0.4% (w
b Eprinomectin 0.4% (w/v).
c M = male, MC = male castrated, F = female, FS = female spayed.
heparinized tubes. Plasma was separated from each sample
and stored frozen in aliquots until analysis.
2.1.3. Plasma sample analysis
A validated, solid-phase extraction method was  used for
the determination of eprinomectin B1a (and other actives)
from plasma, which is brieﬂy described here. After pre-
conditioning/equilibrating a solid-phase extraction plate
(BIOTAGE® Evolute ABN, 25 mg,  Biotage, LLC, Charlotte, NC,
USA) with 1 mL  each of acetonitrile and 0.1% formic acid,
the acidiﬁed plasma sample (250 L plasma + 750 L 1%
formic acid + 50 L internal standard + 50 L acetonitrile)
was loaded onto the plate. The plate was subsequently
rinsed with 1 mL  of 5% methanol in water. Eprinomectin
was eluted with 2× 100 L of acetonitrile, and 50 L of
water was added to the eluate. An aliquot was injected onto
the liquid chromatography–mass spectrometry (LC–MS)
system. In addition to incurred samples, control and for-
tiﬁed quality control (QC) plasma samples were also
assayed with each set. An eprinomectin stock standard
was prepared by dissolving 25 mg  (corrected for purity
and water content) in 25 mL  of acetonitrile. A 10 g/mL
mixed standard solution (ﬁpronil, (S)-methoprene, epri-
nomectin and praziquantel) was then prepared, from
which a series of mixed standards were prepared. Standard
curves were prepared with each set by adding 0.050 mL  of
standard solution (4.0–2500 ng/mL) to 0.250 mL  of control
plasma to yield a standard curve ranging from 0.8 ng/mL
to 500 ng/mL. Quality control (QC) samples were prepared
by adding 0.050 mL  of 5.0, 10, 125 and 2000 ng/mL stan-
dards to 0.250 mL  of control plasma to yield 1.0, 2.0, 25, and
400 ng/mL samples. The standards were injected before
and after each set of samples. All reagents (Merck KgaA,
Darmstadt, Germany) were of the appropriate grade.
The LC–MS system consisted of a Waters Alliance® HT
2795 coupled with a Waters Micromass® Quattro Micro
(Micromass UK Limited, Wythenshawe, Manchester, UK).
Separation was achieved on a Varian Pursuit Diphenyl
column (150 mm × 2 mm,  3 m particle size, catalog num-
ber A3041150x020) coupled with a Sure-Guard disposable
In-Line ﬁlter (stainless steel frit, 0.5 m,  catalog num-
ber 0611-SS05) and Varian Metaguard Pursuit Diphenyl
precolumn (2 mm,  3 m particle size, catalog number
A3041MG2) using a mobile phase consisting of 70:30 ace-
tonitrile/2 mM ammonium acetate buffer (pH 4) at a ﬂow
rate of 0.2 mL/min. The column was maintained at 55 ◦C,praziquantel 8.3% (w/v).
and the autosampler chamber was  maintained at 10 ◦C. The
retention time of eprinomectin B1a was  ∼4 min, and the
transition of 914.5–186.2 m/z was  monitored in the pos-
itive mode. Ethiprole PESTANAL® (Sigma–Aldrich, Batch
SZE8168X, purity 98.3%) was  used as the internal standard
and was  monitored in the negative mode. The validated
limit of quantitation of eprinomectin B1a in cat plasma was
1 ng/mL.
2.1.4. Chromatographic data analyses
MassLynx® 4.1 software was  used to generate and pro-
cess chromatograms. QuanLynx® 4.1 was  used to perform
the linear regression analysis (weighted 1/x,  concentration
versus peak area ratio), and to calculate the concentra-
tion of eprinomectin B1a and the accuracy of the standards
and QC samples. The slope, y-intercept, and coefﬁcient
of determination were determined for each set, and the
unknown concentrations were calculated from the linear
equation. The curve was considered acceptable if the coefﬁ-
cient of determination was  ≥0.99 and contained at least ﬁve
different standard concentrations. Accuracy and precision
were evaluated as percent recovery and reproducibility
(coefﬁcient of variation) of fortiﬁed sample results. The
individual and average percent recoveries in conjunction
with the coefﬁcients of variation of the fortiﬁed samples
were calculated. The overall average recovery was consid-
ered acceptable if it was  between 85% and 115% with a
coefﬁcient of variation of ≤15%.
2.1.5. Pharmacokinetic analysis
Eprinomectin B1a plasma concentrations were deter-
mined for each animal for each sampling time; mean
plasma levels were then determined for each time point
by treatment. Samples with values below the quantita-
tion limit were not used. The following pharmacokinetic
parameters were calculated for each individual animal
using the non-compartmental analysis function of the
WinNonlin® pharmacokinetic software (version 5.0.1,
Pharsight Corp., Mountain View, CA, USA) and then aver-
aged for all animals under the same treatment: the area
under the plasma concentration versus time curve (AUC)
from the time of dosing to the last time point at which
drug concentration was  quantiﬁed, AUC(0–tlast); the AUC
extrapolated to inﬁnity, AUC(0–∞),  the terminal half-life,
t1/2; the volume of distribution at steady-state, Vss; the
total body clearance/clearance rate, CL; and the absolute
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opical bioavailability, F. Maximum plasma concentrations
Cmax) and time to maximum concentration (Tmax) were
he observed values for each animal. The AUC was cal-
ulated using the linear/logarithmic trapezoidal method
hich uses the linear trapezoidal rule up to Cmax and the
ogarithmic trapezoidal rule for the remainder of the curve.
bsolute bioavailability was calculated using the actual
opical dose for each animal and the mean IV dose and
UC(0–tlast) (due to the parallel study design) using the
ormula F = (AUCtopical/Dosetopical)(DoseIV/AUCIV).
To assess the relationship between dose and exposure
Study 2, dose proportionality), a comparison of the aver-
ge dose and exposure ratios (AUC(0–tlast) and dose, and
max and dose) was made; in addition, the Pearson product
oment correlation coefﬁcient (r) for linear regression and
he two-sided p-value were determined (Wessa, 2012. Free
tatistics Software, Ofﬁce for Research Development and
ducation, version 1.1.23-r7, URL http://www.wessa.net/).
he regression lines were based on four treatment groups
f eight animals each.
.2. Evaluation of in vitro metabolism and plasma
rotein binding
.2.1. In vitro metabolism
In vitro metabolic pathways were characterized using
wo lots each of pooled male (n = 3) and pooled female
n = 3) cat liver microsomes and S9 fractions (Celsis In Vitro
echnologies Inc., Baltimore, MD,  USA) in the presence
f unlabelled eprinomectin. Two positive control incu-
ations using 7-hydroxycoumarin and midazolam were
ncluded to verify oxidation, glucuronidation, and sulfation
apabilities of the male and female cat liver microsomes
nd S9 fractions. The enzyme cofactors tested included
he NADPH regeneration system (the cofactor for P450
nzymes), UDPGA (the cofactor for uridine glucuronyl
ransferases), and PAPS (the cofactor for sulfotransferases).
prinomectin (125 L, 0.4 M)  in 50 mM phosphate buffer
as incubated with 250 L male or female microsomes
1 mg/mL) or S9 fractions (2 mg/mL) and 125 L of the
ofactor at 37 ◦C in a shaking water bath. Aliquots of 50 L
ere taken from the incubation solution at 0, 30, 60, 120,
nd 240 min. The reaction was stopped by the addition of
50 L of acetonitrile containing the internal standard. The
amples were vortex mixed followed by centrifugation for
0 min  at 3310 × g and then analyzed by LC–MS. The pos-
tive controls used 50 L of 2 mg/mL  male or female liver
icrosomes or S9 fraction in buffer, 25 L of 4 M mida-
olam or 100 M 7-hydroxycoumarin (7-HC) in buffer, and
5 L of the NADPH regeneration solution, UDPGA, or PAPS.
lamethicin (25 g/mL) was included in the UDPGA incu-
ation cocktail to facilitate transport of UDPGA to the active
ite. After incubation in a water bath with gentle shaking
or 1 h, the reaction was stopped by the addition of 300 L
cetonitrile containing the internal standard. The super-
atants were analyzed by LC–MS after centrifugation for
0 min  at 3310 × g..2.2. Protein binding
Equilibrium dialysis (Dianorm Multi-Equilibrium
IALYZERTM) was used to determine the degree of proteinasitology 202 (2014) 2–9 5
binding of eprinomectin. The experiments were conducted
with three different lots of cat, dog, and rat plasma (EDTA
treated; Bioreclamation, West Meadow, NY, USA) fortiﬁed
at three concentrations, 10, 50, and 500 ng/mL. Aliquots
of 1 mL  of fortiﬁed plasma were placed in one side of the
chamber and 1 mL  of isotonic phosphate buffer (pH 7.4)
was placed in the other side. The chambers were separated
by a semi-permeable cellulose membrane with a molecu-
lar weight cutoff (MWCO) of 10,000 Da. After incubation
for approximately 4 h at 37 ◦C, aliquots from both sides of
the chamber (plasma and buffer) were taken and analyzed
by a LC–MS method to determine the concentration of
unbound eprinomectin.
3. Results
3.1. Plasma sample analysis
The bioanalytical method was selective, accurate, and
reproducible for the analysis of eprinomectin B1a from
cat plasma. There were no interferences from endogenous
plasma compounds or the other analytes. Fortiﬁed and
unfortiﬁed control plasma samples were analyzed with
each set. Samples were fortiﬁed at 1, 2, 25, and 400 ng/mL,
and the average percent recovery (interday accuracy) at
each level was 102, 92, 94, and 97, respectively, with the
coefﬁcient of variation (interday precision) less than 13%
in all cases. The grand average across all fortiﬁed samples
(n = 47) was  96 ± 10%. For the dose proportionality study,
the average percent recovery at each level was  98, 97, 94,
and 98, respectively, with a coefﬁcient of variation of 8% or
less for each level. The grand average (n = 73) was 96 ± 7%.
3.2. Pharmacokinetic analysis
Topical eprinomectin was  absorbed with an absolute
bioavailability of 31%. An average Cmax of 20 ng/mL was
obtained at an average Tmax of 48 h. AUC(0–tlast) was
1880 ng h/mL on average, and the half-life was 114 h (4.75
days). The clearance rate of intravenously administered
eprinomectin was 81 mL/h/kg and the volume of distri-
bution at steady state was  2390 mL/kg. The elimination
followed a bi-exponential decay with a half-life of 23 h.
Pharmacokinetic parameters from both the topical and
IV routes of administration are summarized in Table 2.
The plasma concentration time proﬁles of the individ-
ual animals are shown in Figs. 1 and 2, and the average
concentration–time proﬁles are plotted in Fig. 3. Animal
293 in Treatment Group 1 had the highest plasma con-
centrations of all topically treated animals, perhaps due to
ingestion from grooming.
Drug exposure was proportional to dose in the range
of 0.25–2.5 mg/kg bodyweight, or 0.5–5 times the rec-
ommended minimum dose, as illustrated by the average
plasma concentration time curves (Fig. 4), and by compari-
son of the dose and exposure (AUC(0–tlast) and Cmax) ratios
(Table 3 and Fig. 5), though slightly under proportional at
5×. The square of the Pearson product moment correlation
coefﬁcient (r) for linear regression between AUC(0–tlast)
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Table 2
Summary of the pharmacokinetic parameters of eprinomectin following a single topical dose administration of Broadline® (including eprinomectin at
0.5  mg/kg bodyweight) or an intravenous eprinomectin formulation (0.4 mg/kg eprinomectin) to cats.
Parametera Topical eprinomectin, n = 8 Intravenous eprinomectin, n = 6
Mean ± SDb CVc (%) Mean ± SD CV (%)
Tmax (h) 48 ± 51 107 NAd NA
Cmax (ng/mL) 20.1 ± 26.9 133 503 ± 88 17
C0 (ng/mL) NA NA 548 ± 107 19
AUC(0–tlast) (ng h/mL) 1880 ± 813 43 5080 ± 987 19
AUCinf (ng h/mL) 2100 ± 768 37 5160 ± 983 19
%  AUC extrapolated 11.9 ± 5.4 46 1.69 ± 1.17 69
Terminal half-life (h) 114 ± 37 33 23.1 ± 7.0 30
CL  (mL/h/kg) NA NA 80.8 ± 14.9 18
Vss  (mL/kg) NA NA 2390 ± 595 25
a Tmax, time to maximum concentration; Cmax, maximum plasma concentration; C0, concentration extrapolated to time 0; AUC(0–tlast) or (0–∞),  area
under  the plasma concentration versus time curve from the time of dosing to the last time point at which drug concentration was quantiﬁed or extrapolated
to  inﬁnity; %AUC extrapolated, percent of AUC, extrapolated to inﬁnity; CL, total body clearance; Vss, volume of distribution at steady-state.
b Standard deviation.
c Coefﬁcient of variation.
d Not applicable.
Fig. 1. Plasma concentration over time (days) of eprinomectin B1a [epr]
in  individual cats after topical administration of a single dose of 0.5 mg/kg
Fig. 2. Plasma concentration over time (days) of eprinomectin B1 [epr]bodyweight in the combination formulation consisting of ﬁpronil 8.3%
(w/v), (S)-methoprene 10% (w/v), eprinomectin 0.4% (w/v) and praziquan-
tel 8.3% (w/v).
and dose and Cmax and dose was 0.9703 and 0.9393, respec-
tively.
3.3. In vitro metabolism and protein binding
To assess in vitro metabolic pathways, eprinomectin
was incubated with one lot of pooled male and one lot
of pooled female cat liver microsomes and S9 fractions.
The resulting samples were analyzed by LC–MS to quantify
eprinomectin B1a and determine the disappearance rate.
In general, the liver microsomes showed greater metabolic
activity than the S9 fractions. It was determined that epri-
nomectin was very metabolically stable and not subject
Table 3
Nominal dose ratios versus calculated mean exposure ratios (Cmax and AUC) of ep
Eprinomectin dose Dose ratio Cmax (ng/
Mean 
0.25 mg/kg topically 0.5 6.90 
0.5  mg/kg topically 1 16.1 
1  mg/kg topically 2 33.7 
2.5  mg/kg topically 5 54.1 a
in individual cats after intravenous administration of a single dose of
0.4  mg/kg bodyweight in a 0.4% (w/v) eprinomectin formulation.
to phase II metabolism. Conjugates of eprinomectin were
not observed after incubation with the glucuronidation
and sulfation cofactors UDPGA and PAPS. In the male and
female liver microsomes, the in vitro half-life was 7.8
or 29 h, respectively, and the intrinsic clearance was 3.5
or 1.8 mL/min/kg, respectively. Eprinomectin was deter-
mined to be a low hepatic extraction ratio drug, with values
of 0.12 or 0.06, respectively. To further evaluate gender
related metabolism, an additional lot each of male and
female microsomes were obtained and evaluated. It was
inconclusive as to whether there was gender dependent
eprinomectin metabolism; it appeared to correlate with
relative CYP3A4 activity data. One lot of pooled microsomes
(male) had CYP3A4 activity almost threefold greater than
the other lots (one male and two female).
rinomectin following single dose administrations of Broadline® to cats.
mL) AUC(0–tlast) (ng h/mL)
Ratio Mean Ratio
0.43 1140 0.44
1.00 2570 1.00
2.09 5040 1.97
3.35 9000 3.51
V. Kvaternick et al. / Veterinary Par
Fig. 3. Average (±standard deviation) plasma concentration over time
(days) of eprinomectin B1a [epr] in cats after topical (0.5 mg/kg
bodyweight, n = 8) or intravenous (IV, 0.4 mg/kg bodyweight, n = 6) admin-
istration.
Fig. 4. Average (±standard deviation, n = 8, each) plasma concentration
over time (days) of eprinomectin B1a [epr] after a single topical admin-
istration of eprinomectin at 0.5, 1, 2, or 5 times the recommended dose
o
ﬁ
a
d
t
b
t
a
n
s
F
p
l
af  0.5 mg/kg bodyweight in the combination formulation consisting of
pronil 8.3% (w/v), (S)-methoprene 10% (w/v), eprinomectin 0.4% (w/v)
nd praziquantel 8.3% (w/v).
The amount of drug bound to plasma proteins was
etermined as the percent of total drug added (%pro-
ein binding = 100 × (total − unbound)/total). The average
inding of eprinomectin to cat plasma proteins at concen-
rations ranging from 10 ng/mL to 500 ng/mL was  99.5%,
nd the variability in binding between concentrations was
egligible. The percent bound was also similar across
pecies, 99.4% in rat and 99.6% in dog.
ig. 5. Proportionality of dose and exposure for both area under the
lasma concentration versus time curve from the time of dosing to the
ast  time point at which drug concentration was quantiﬁed, AUC(0–tlast),
nd maximum plasma concentration (Cmax).asitology 202 (2014) 2–9 7
4. Discussion
The pharmacokinetics of eprinomectin have also been
studied in rabbits, donkeys, sheep, and goats (Dupuy et al.,
2001; Kozˇuh Erzˇen et al., 2007; Wen  et al., 2010a; Gokbulut
et al., 2012). Alongside other macrocyclic lactones such as
milbemycin, selamectin, and ivermectin that are used to
treat cats (Nolan and Lok, 2012), eprinomectin exhibits
slow topical absorption, high protein binding, extensive
distribution, minimal biotransformation, and slow bil-
iary excretion (Sarasola et al., 2002; Chittrakarn et al.,
2009; González Canga et al., 2009). In contrast, the der-
mal  bioavailability of selamectin in cats is much higher
(74%) than eprinomectin (Sarasola et al., 2002). The abso-
lute bioavailability of topically applied eprinomectin in cats
is comparable to that in cattle, 31% versus 29%, respec-
tively, (Merial, unpublished data). Licking or self-grooming
behaviors may  result in an increased variability of exposure
(Wen  et al., 2010a; Rehbein et al., 2012). Plasma concen-
tration proﬁles of the individual cats and coefﬁcients of
variation of pharmacokinetic parameters indicate some
variation in exposure between cats which might be related
to a different extent of grooming and thus oral ingestion of
topically applied eprinomectin, as grooming was  observed
for several cats in each treatment group.
In the ﬁrst study to compare topically and intravenously
administered eprinomectin in cats, the concentration time
proﬁles indicate an absorption dependent decay in ter-
minal plasma concentrations of topically administered
eprinomectin, what is commonly termed ‘ﬂip-ﬂop’ kinet-
ics. The average half-life is 114 h (4.75 days) for topical
dosing and 23 h for intravenous dosing. A prolonged
absorption is a common characteristic of topically applied
macrocyclic lactones, for example, selamectin applied top-
ically to cats achieves a maximum concentration 15 h after
treatment and has a half-life of approximately eight days,
which is substantially longer than that following intra-
venous administration (Sarasola et al., 2002). The terminal
half-life of eprinomectin varies among species. The epri-
nomectin half-life in cats (topical) is approximately 2.7
times longer than the half-life of topically applied epri-
nomectin in rabbits (Wen  et al., 2010a), approximately 1.4
times longer than that in cattle unrestricted from groom-
ing (Merial, unpublished data), variable in cattle restricted
from grooming (Wen  et al., 2010b; Rehbein et al., 2012) and
similar or slightly shorter than that in sheep and donkeys
(Hodoscek et al., 2008; Gokbulut et al., 2012). These
variations may  be due to differences in the pharmacoki-
netic analysis model, formulations, dermal characteristics,
species related differences, and/or additional absorption
via grooming for some species. On the other hand, the half-
life of eprinomectin is much shorter than that reported for
selamectin (Sarasola et al., 2002), and may  be due in part
to eprinomectin’s molecular structure and resulting effect
on plasma and tissue kinetics, for example, eprinomectin
has a low milk to plasma ratio (Shoop et al., 1996b).
While one of the least lipophilic (log P = 4) macrocyclic
lactones (Kiki-Mvouaka et al., 2010), eprinomectin has a
volume of distribution of 2390 mL/kg, which suggests it is
well distributed throughout the body. In fact, this value is
rather large compared to the blood volume of cats which
inary Pa8 V. Kvaternick et al. / Veter
is ∼75 mL/kg (Chittrakarn et al., 2009). This was  substanti-
ated by the results of multiple efﬁcacy studies targeting
intestinal, urinary bladder, and cardiopulmonary worms
completed during the registration process.
As reported for rats and cattle, eprinomectin is excreted
mainly unchanged in the feces, with the major metabo-
lite being deacetylated eprinomectin, a result of phase I
metabolism (nonsynthetic metabolism) (EMEA, 1996; Zeng
et al., 1996). This pattern of minimal biotransformation and
formation of deacetylated eprinomectin was also observed
in in vitro studies using sheep, cattle, and goat liver micro-
somes (Merial, unpublished data). A similar pattern was
demonstrated in our in vitro metabolism studies using
cat liver microsomes which indicated that eprinomectin
was not subject to phase II metabolism, for example, glu-
curonide conjugates were not synthesized. This is in line
with the fact that cats are deﬁcient in the ability to glu-
curonidate many drugs to facilitate elimination (Court
and Greenblatt, 1997a; Tanaka et al., 2006). Glucuronida-
tion reactions are catalyzed by a group of more than 26
isozymes (Court and Greenblatt, 1997b) and it appears that
cats have a less diverse pattern of UGT1A isoforms. It is
postulated that this could be due to the fact that they are
obligatory carnivores, that is, it is related to their diet and
other metabolic processes (Court and Greenblatt, 2000).
In a study to compare the in vitro metabolic activ-
ity of the various P450 enzymes in cats, dogs, horses,
and humans, the least activity for cats was observed for
the 2C8/9 subfamily (Chauret et al., 1997). This was also
conﬁrmed in a study by Shah et al. (2007). Phenacetin O-
deethylase activity (CYP1A) was greatest in cats (Chauret
et al., 1997). Work by Tanaka et al. (2006) to characterize
the P450 cytochromes responsible for phase I metabolism
in cats indicated that the CYP1A isoform is active and
involved in the oxidation of many drugs. Furthermore, Shah
et al. (2007) reported this as a gender independent path-
way. In addition, it has been reported that ivermectin, an
avermectin closely related to eprinomectin, is primarily
metabolized by the CYP3A4 isozyme by human liver micro-
somes (Merck & Co., 2010) which correlates with the degree
of eprinomectin metabolism noted for different lots of the
cat liver microsomes with different CYP3A4 activity. While
Shah et al. (2007) reported that the in vitro CYP3A4 activity
was ﬁvefold higher in male cats compared to female cats, in
our study in vitro metabolic gender differences were incon-
clusive and were attributed to the activity of CYP3A4. In our
studies, one lot of male liver microsomes had CYP3A4 activ-
ity (262 pmol/min/mg) approximately 3 times greater than
that of the other lot of male liver microsomes and the two
lots of female liver microsomes.
5. Conclusion
Eprinomectin administered topically to cats is slowly
and moderately absorbed. Following topical administra-
tion, the half-life is approximately 5 times longer than
after intravenous administration and indicates absorption
dependent or ‘ﬂip-ﬂop’ kinetics. Clearance was dose inde-
pendent, and drug exposure was proportional to dose
over a tenfold dose range. In cats, eprinomectin is highlyrasitology 202 (2014) 2–9
protein bound, widely distributed, and undergoes minimal
biotransformation.
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